AGO-Zervix-1研究主要结果:比较紫杉醇联合拓扑替康与顺铂联合拓扑替康治疗复发性和持续性宫颈癌的前瞻性随机III期研究
AGO-Zervix-1研究为前瞻性随机III期试验,计划入组312例,实际入组173例复发或转移性宫颈癌患者,1:1随机接受拓扑替康联合紫杉醇(TP)或拓扑替康联合顺铂(TC)治疗。TP组中位总生存9.6个月,TC组12.0个月(P=0.33),中位无进展生存分别为4.4个月和4.2个月(P=0.47)。结论认为含铂联合化疗仍是复发或转移性宫颈癌的标准治疗方案。
要点
- TP组中位总生存9.6个月,TC组12.0个月,差异无统计学意义(P=0.33)。
- TP组中位无进展生存4.4个月,TC组4.2个月,差异无统计学意义(P=0.47)。
- 含顺铂组白细胞减少和恶心呕吐更常见,其余毒性可比,生活质量无差异。
核心结论
- 含铂联合化疗仍是复发或转移性宫颈癌的标准治疗化疗方案。
研究设计与样本
- AGO-Zervix-1研究(NCT01405235)为前瞻性随机III期研究,计划入组312例,实际入组173例患者。
- 患者按1:1随机分配至对照组(拓扑替康0.75 mg/m2第1-3天联合顺铂50 mg/m2第1天,每3周)或研究组(拓扑替康1.75 mg/m2联合紫杉醇70 mg/m2第1、8、15天,每4周)。
- 主要研究终点为总生存,次要终点包括无进展生存、毒性和生活质量。
主要发现
- TP组中位总生存9.6个月,TC组12.0个月(log-rank检验,P=0.33)。
- TP组中位无进展生存4.4个月,TC组4.2个月(log-rank检验,P=0.47)。
- 含顺铂组白细胞减少和恶心呕吐更频繁,其余毒性特征相当。
- FACT-G评估的生活质量无差异。
关键数值与推荐
- 对照组方案:拓扑替康0.75 mg/m2第1-3天联合顺铂50 mg/m2第1天,每3周。
- 研究组方案:拓扑替康1.75 mg/m2联合紫杉醇70 mg/m2第1、8、15天,每4周。
临床怎么用
- 原文结论认为含铂联合化疗仍是复发或转移性宫颈癌的标准治疗化疗方案。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Before the era of immunotherapies and antibody-drug conjugates, there were limited chemotherapeutic options for patients with recurrent and metastatic cervical cancer. Combination therapies with cisplatin have shown some superiority over monotherapy. This study examined platinum-free treatment regimens, comparing a combination of topotecan and paclitaxel (TP) with topotecan and cisplatin (TC) in patients with recurrent or metastatic cervical cancer, with or without prior platinum-based treatment. METHODS: The AGO-Zervix-1 Study (NCT01405235) is a prospective, randomized phase III study in which patients were randomly assigned at a 1:1 ratio to treatment within the control arm with topotecan (0.75 mg/m2) on days 1-3 and cisplatin (50 mg/m2) on day 1 every 3 weeks and in the study arm topotecan (1.75 mg/m2) and paclitaxel (70 mg/m2) on days 1, 8, and 15 every 4 weeks or treatment. The primary study aim was overall survival; progression-free survival, toxicity, and quality of life were secondary aims. The interim and final analysis is here reported after recruitment of 173 of 312 planned patients. RESULTS: Median overall survival in the TP arm was 9.6 months, compared with 12.0 months in the TC arm (log-rank test, P = 0.33). Median progression-free survival rates were 4.4 months with TP and 4.2 months with TC (log-rank test, P = 0.47). Leukopenia and nausea/vomiting were more frequent in the cisplatin-containing arm. Otherwise, toxicity profiles were comparable. There were no differences in FACT-G-assessed quality of life. CONCLUSION: Platinum-based combination chemotherapy remains the standard of care chemotherapy regimen for patients with recurrent or metastatic cervical cancer.
引用
- Gass P, Thiel FC, Häberle L, et al. Primary results of the AGO-Zervix-1 Study: A prospective, randomized phase III study to compare the effects of paclitaxel and topotecan with those of cisplatin and topotecan in the treatment of patients with recurrent and persistent cervical cancer. Gynecol Oncol. 2024. PMID: 38490057. doi:10.1016/j.ygyno.2024.03.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。